Loki Home

Research Interests

Funding Opportunities

FAQ

UI Login Guest Login

Browse by Investigator Last Name



Browse Research


Photo of Kimberly Leslie

Kimberly Leslie

Professor,  Obstetrics & Gynecology

Contact Information

Phone: +1 319 356 1976
Email: kimberly-leslie@uiowa.edu
Web:

Education

BS, Psychology, Baylor University, Waco, TX
BS, Biology and Biochemistry, Texas Christian University, Fort Worth, TX
MD, Medicine, Southwestern Medical School, University of Texas, Dallas, TX
Residency, Obstetrics and Gynecology, Parkland Memorial Hospital, Dallas, TX
Residency, Obstetrics and Gynecology, Georgetown University Affiliated Hospitals, Washington, DC
Fellowship, Maternal-fetal Medicine, Georgetown University, Washington, DC

Appointments

Primary: Obstetrics & Gynecology

Centers and Program Affiliations

Interdisciplinary Graduate Program in Molecular and Cellular Biology

Research Interests


MeSH Terms from Publications

Endometrial Neoplasms, Receptors, Progesterone, Female, Progesterone, Humans, Cell Line, Tumor, Pregnancy, Gene Expression Regulation, Neoplastic, Pregnancy Complications, Neoplastic, Cell Cycle, Mice, Nude, Antibodies, Monoclonal, Transfection, Receptors, Steroid, Tumor Suppressor Protein p53, Amniotic Fluid, Animals, Antineoplastic Agents, Xenograft Model Antitumor Assays, Receptors, Estrogen, Antibodies, Monoclonal, Humanized, Paclitaxel, Estriol, Pregnancy Complications, Infectious, Amifostine

Research Summary



Recent Publications


Show publications
  1. Yang, S, Xiao, X, Meng, X, Leslie, K. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 6(10):e26343, 2011. [PubMed]
  2. Yang, S, Thiel, K, De Geest, K, Leslie, K. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 12(64):205-12, 2011. [PubMed]
  3. Meng, X, Brachova, P, Yang, S, Xiong, Z, Zhang, Y, Thiel, K, Leslie, K. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. PLoS One 6(6):e20920, 2011. [PubMed]
  4. Yang, S, Thiel, K, Leslie, K. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 22(4):145-52, 2011. [PubMed]
  5. Davies, S, Dai, D, Pickett, G, Thiel, K, Korovkina, V, Leslie, K. Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance. Oncol Rep 25(3):855-62, 2011. [PubMed]
  6. Bolnick, J, Albitar, L, Laidler, L L, Abdullah, R, Leslie, K K. Blocking Epidermal Growth Factor Receptor Signaling in HTR-8/SVneo First Trimester Trophoblast Cells Results in Dephosphorylation of PKB?/AKT and Induces Apoptosis. Obstet Gynecol Int 2011:896896, 2011. [PubMed]
  7. Singh, M, Darcy, K, Brady, W, Clubwala, R, Weber, Z, Rittenbach, J, Akalin, A, Whitney, C, Zaino, R, Ramirez, N, Leslie, K. Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial. Gynecol Oncol 123(2):320-8, 2011. [PubMed]
  8. Aghajanian, C, Sill, M, Darcy, K, Greer, B, McMeekin, D, Rose, P, Rotmensch, J, Barnes, M, Hanjani, P, Leslie, K. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 29(16):2259-65, 2011. [PubMed]
  9. Schickling, B, Aykin-Burns, N, Leslie, K, Spitz, D, Korovkina, V. An inhibitor of K+ channels modulates human endometrial tumor-initiating cells. Cancer Cell Int 11(1):25, 2011. [PubMed]
  10. Santillan, M, Santillan, D, Hamilton, W, Hunter, S, Leslie, K, Rayburn, W. Adaptations in maternal sera of immuno-vasoactive IDO, trail, and IL-4 in response to a high sFLT-1 preeclamptic environment. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 204(null):S303-S304, JAN 2011.